Lucinda Billingham is Professor of Biostatistics within the Institute of Cancer and Genomic Sciences at the University of Birmingham. She has worked for over twenty years as a Biostatistician at their Cancer Research UK Clinical Trials Unit and is now Director of Statistics for the Unit working with a large team of Biostatisticians on an extensive portfolio of early and late phase trials. As part of this role, she provides statistical leadership for the Drugs, Devices, Diagnostics and Biomarkers (D3B) Clinical Trials Team within the Institute of Translational Medicine. She is a selected member for the National Cancer Research Institute Lung Cancer Clinical Studies Group and the British Thoracic Oncology Group Steering Committee and is an invited member of the Cancer Research UK Clinical Expert Review Panel providing statistical advice for funding applications.
Lucinda has a special interest in lung cancer and sarcoma research and is the Chief Biostatistician for the National Lung Matrix Trial. As well as her PhD research on statistical methods for the simultaneous analysis of quality of life and survival data, other key areas of expertise include application of Bayesian methods in trials, design and analysis of trials in rare cancers, early phase trial design and statistical methodology for biomarker discovery, validation and evaluation for stratified medicine. She lectures on a number of undergraduate and postgraduate courses at Birmingham, teaches widely on external courses and provides PhD supervision.